Corient Private Wealth LP Purchases Shares of 122,491 Kura Oncology, Inc. $KURA

Corient Private Wealth LP acquired a new position in Kura Oncology, Inc. (NASDAQ:KURA) during the 2nd quarter, Holdings Channel.com reports. The institutional investor acquired 122,491 shares of the company’s stock, valued at approximately $1,344,000.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in KURA. IFP Advisors Inc increased its stake in shares of Kura Oncology by 115.3% in the fourth quarter. IFP Advisors Inc now owns 2,398 shares of the company’s stock worth $25,000 after purchasing an additional 1,284 shares in the last quarter. Allworth Financial LP raised its holdings in Kura Oncology by 59.9% during the fourth quarter. Allworth Financial LP now owns 4,146 shares of the company’s stock valued at $43,000 after acquiring an additional 1,553 shares during the period. EverSource Wealth Advisors LLC boosted its stake in shares of Kura Oncology by 49.0% in the fourth quarter. EverSource Wealth Advisors LLC now owns 5,742 shares of the company’s stock worth $60,000 after acquiring an additional 1,888 shares during the period. Insigneo Advisory Services LLC purchased a new stake in shares of Kura Oncology during the fourth quarter worth about $105,000. Finally, LPL Financial LLC bought a new stake in Kura Oncology during the 4th quarter valued at approximately $105,000.

Analyst Ratings Changes

A number of equities research analysts have issued reports on KURA shares. Citizens Jmp reaffirmed a “market outperform” rating and set a $24.00 price objective on shares of Kura Oncology in a report on Monday, August 24th. Wall Street Zen raised shares of Kura Oncology from a “strong sell” rating to a “hold” rating in a report on Saturday, May 16th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Kura Oncology in a research report on Friday, July 17th. CLSA set a $24.00 price target on Kura Oncology in a report on Thursday, June 4th. Finally, Wedbush boosted their target price on shares of Kura Oncology from $36.00 to $38.00 and gave the stock an “outperform” rating in a report on Thursday, August 13th. Ten research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $25.40.

Kura Oncology Trading Up 0.8%

Shares of NASDAQ KURA opened at $13.25 on Friday. The company has a quick ratio of 4.71, a current ratio of 4.73 and a debt-to-equity ratio of 0.12. The business has a fifty day simple moving average of $11.11 and a two-hundred day simple moving average of $9.81. The firm has a market cap of $1.18 billion, a PE ratio of -3.93 and a beta of 0.44. Kura Oncology, Inc. has a twelve month low of $7.36 and a twelve month high of $13.90.

Kura Oncology (NASDAQ:KURA) last issued its earnings results on Wednesday, August 12th. The company reported ($0.77) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.88) by $0.11. Kura Oncology had a negative net margin of 384.30% and a negative return on equity of 207.18%. The company had revenue of $20.87 million for the quarter, compared to analysts’ expectations of $20.16 million. Analysts expect that Kura Oncology, Inc. will post -3.25 earnings per share for the current fiscal year.

Insider Buying and Selling at Kura Oncology

In related news, insider Brian Powl sold 4,345 shares of the business’s stock in a transaction that occurred on Friday, August 21st. The shares were sold at an average price of $11.89, for a total value of $51,662.05. Following the completion of the transaction, the insider owned 169,269 shares of the company’s stock, valued at $2,012,608.41. The trade was a 2.50% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Teresa Bair sold 31,487 shares of the stock in a transaction on Wednesday, August 19th. The shares were sold at an average price of $12.63, for a total value of $397,680.81. Following the sale, the insider directly owned 195,444 shares in the company, valued at $2,468,457.72. This trade represents a 13.88% decrease in their position. The SEC filing for this sale provides additional information. In the last three months, insiders sold 120,761 shares of company stock valued at $1,283,346. 7.60% of the stock is owned by corporate insiders.

About Kura Oncology

Kura Oncology, Inc (NASDAQ: KURA) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted oncology therapies. Headquartered in La Jolla, California, the company leverages expertise in molecular biology and precision medicine to identify key drivers of cancer growth and design small-molecule inhibitors that block those pathways. Kura’s research platform integrates genomic insights with medicinal chemistry to advance candidates against well-validated targets in solid tumors and hematologic malignancies.

The company’s lead clinical candidate, tipifarnib, is a farnesyltransferase inhibitor being evaluated for the treatment of HRAS-mutant head and neck squamous cell carcinoma and various non-small cell lung cancers.